1. Home
  2. LYEL

LYEL

Lyell Immunopharma Inc.

Logo Lyell Immunopharma Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-22-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.

Founded: 2018 Country:
United States
United States
Employees: N/A City: SOUTH SAN FRANCISCO
Market Cap: 566.6M IPO Year: 2021
Target Price: $5.50 AVG Volume (30 days): 927.5K
Analyst Decision: Buy Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.93 EPS Growth: N/A
52 Week Low/High: $1.32 - $3.97 Next Earning Date: 05-02-2024
Revenue: $130,000 Revenue Growth: -99.85%
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: